Bioavailability and Pharmacodynamics of EPA and DHA From Fortified Soymilk and Capsules
Launched by OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER · Apr 4, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well a fortified soymilk made with algae oil works in comparison to a commercial algae oil capsule. Both products contain similar beneficial nutrients called EPA and DHA, which are important for heart health. The goal is to see if drinking the soymilk can help the body absorb these nutrients just as well, or even better, than taking the capsules.
To participate in this study, you should be between 18 and 75 years old and have a body mass index (BMI) between 18 and 30, which means you should be within a healthy weight range. However, there are some important exclusions: if you are pregnant, have certain health conditions like diabetes or high cholesterol, or are currently taking specific medications or supplements related to omega-3 fatty acids, you may not be eligible. Participants can expect to provide blood samples to measure how well their bodies absorb the nutrients and will be closely monitored throughout the study. This research is currently looking for volunteers, so if you're interested and meet the criteria, this could be a great opportunity to contribute to our understanding of nutrition!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Body mass index between 18 and 30 kg/m2
- Exclusion Criteria:
- • Being pregnant or nursing
- • Having anemia or a condition that influences the ability to donate blood safely
- • Allergies to the beverage or pill ingredients
- • Diabetes
- • High triglycerides or cholesterol
- • Coagulation disorder
- • Anticoagulation therapy or any drug that affects blood clotting.
- • Taking prescribed dietary omega-3 fatty acid medications including fish oil or algae oil within the last 3 months
- • Taking non-prescribed dietary omega-3 fatty acid supplements within the last 3 months and not willing to discontinue taking them for the study period
- • Taking lipid lowering medications such as statins
- • Sensory impairments which affect ability to taste, smell, or see food products
About Ohio State University Comprehensive Cancer Center
The Ohio State University Comprehensive Cancer Center (OSUCCC) is a leading institution dedicated to advancing cancer research, treatment, and education. As a National Cancer Institute-designated comprehensive cancer center, OSUCCC integrates cutting-edge research with clinical practice to develop innovative therapies and improve patient outcomes. With a collaborative approach that unites scientists and clinicians, OSUCCC focuses on personalized medicine, cancer prevention, and community outreach, striving to enhance the understanding of cancer biology and provide hope to patients through groundbreaking clinical trials and comprehensive care programs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Patients applied
Trial Officials
Yael Vodovotz, PhD
Principal Investigator
Ohio State University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials